Compare
Achieve Life Sciences, Inc. vs Immucell Corp vs Insight Molecular Diagnostics Inc. vs Alpha Teknova, Inc.
| Latest fiscal year | Achieve Life Sciences, Inc. ACHV | Immucell Corp ICCC | Insight Molecular Diagnostics Inc. IMDX | Alpha Teknova, Inc. TKNO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $27.64M | $4.05M | $40.52M |
| Revenue growth (YoY) | n/a | +4.3% | +115.6% | +7.4% |
| Gross margin | n/a | 41.4% | 56.7% | 33.2% |
| Operating margin | n/a | 6.0% | n/m | -41.9% |
| Net margin | n/a | -3.8% | n/m | -42.6% |
| Net income | -$54.65M | -$1.04M | -$50.22M | -$17.26M |
| EPS (Diluted) | -$1.25 | -$0.12 | -$1.65 | -$0.32 |
| Operating cash flow | -$49.47M | $2.48M | -$22.18M | -$8.65M |
| Free cash flow | -$49.47M | $1.22M | -$25.37M | -$9.79M |
| Cash & equivalents | $20.93M | $3.81M | $11.58M | $5.91M |
| Total assets | $41.79M | $42.53M | $25.76M | $103.58M |
| Total liabilities | $20.27M | $15.48M | $57.22M | $34.81M |
| Shareholders' equity | $21.52M | $27.06M | -$31.46M | $68.78M |
| Return on year-end equity | -254.0% | -3.8% | n/a | -25.1% |
| Shares outstanding | 53.23M | 9.05M | 28.68M | 53.56M |
Revenue, most recent five fiscal years
| Fiscal year | Achieve Life Sciences, Inc. | Immucell Corp | Insight Molecular Diagnostics Inc. | Alpha Teknova, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2019-12-31 | $27.64M Ended 2025-12-31 | $4.05M Ended 2025-12-31 | $40.52M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2018-12-31 | $26.49M Ended 2024-12-31 | $1.88M Ended 2024-12-31 | $37.74M Ended 2024-12-31 |
| 2 years earlier | n/a | $17.47M Ended 2023-12-31 | $1.50M Ended 2023-12-31 | $36.68M Ended 2023-12-31 |
| 3 years earlier | n/a | $18.57M Ended 2022-12-31 | $958.0K Ended 2022-12-31 | $41.42M Ended 2022-12-31 |
| 4 years earlier | n/a | $19.24M Ended 2021-12-31 | $2.20M Ended 2021-12-31 | $36.89M Ended 2021-12-31 |